)
)
)
Hopstem Biotechnology
Hopstem aims to develop innovative iPSC cell therapy for global CNS patients. The potential RMAT, BIC and FIC hNPC01 injection received IND clearance from FDA and NMPA, completed Phase I study for chronic stroke in June 2025. Hear us @ Jun 17 11:45 153C.
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
